Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760984 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2PIK3CDPIK3CA | |
| SCHEMBL1760925 | 0.95 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2PIK3CDPIK3CA | |
| SCHEMBL2931638 | 0.88 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2PIK3CDPIK3CA | |
| SCHEMBL2932725 | 0.88 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2PIK3CDPIK3CA | |
| SCHEMBL2931691 | 0.87 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2PTK2LRRK2 | |
| SCHEMBL1760967 | 0.86 | PIK3CD (0.42) | PIK3CDPIK3CARIPK1PIK3CBPIK3CG | |
| SCHEMBL12592897 | 0.86 | PIK3CD (0.42) | PIK3CDPIK3CARIPK1PIK3CBPIK3CG | |
| SCHEMBL1761048 | 0.84 | HPGDS (0.44) | PIK3CDPIK3CALRRK2PIK3CBPIK3CG | |
| SCHEMBL1761043 | 0.83 | PIK3CD (0.40) | PIK3CDPIK3CARIPK1PIK3CBPIK3CG | |
| SCHEMBL4049256 | 0.81 | PIK3CD (0.41) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | TAS1R3 431/4885TAS1R1 312/4885TAS1R2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.